U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H26Cl2N4
Molecular Weight 417.375
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NBI-34041

SMILES

CCCC(CCC)N1CCN2N=C(C3=NC(C)=CC1=C23)C4=C(Cl)C=C(Cl)C=C4

InChI

InChIKey=AKLMUGFDGONMAA-UHFFFAOYSA-N
InChI=1S/C22H26Cl2N4/c1-4-6-16(7-5-2)27-10-11-28-22-19(27)12-14(3)25-21(22)20(26-28)17-9-8-15(23)13-18(17)24/h8-9,12-13,16H,4-7,10-11H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C22H26Cl2N4
Molecular Weight 417.375
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 12:02:12 GMT 2023
Edited
by admin
on Sat Dec 16 12:02:12 GMT 2023
Record UNII
874OEY3JEJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NBI-34041
Common Name English
SB-723620
Code English
1-(2,4-DICHLOROPHENYL)-5-(HEPTAN-4-YL)-7-METHYL-4,5-DIHYDRO-3H-2,2A,5,8-TETRAAZAACENAPHTHYLENE
Systematic Name English
SB723620
Code English
6H-1,3,6,8A-TETRAAZAACENAPHTHYLENE, 2-(2,4-DICHLOROPHENYL)-7,8-DIHYDRO-4-METHYL-6-(1-PROPYLBUTYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
874OEY3JEJ
Created by admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
PRIMARY
CAS
268545-87-5
Created by admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
PRIMARY
PUBCHEM
9888194
Created by admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
NBI-34041
Created by admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
PRIMARY Description: NBI-34041 is potent and high-affinity CRF1 receptor antagonist. NBI-34041 is safety and efficacy in attenuating elevated stress response. NBI-34041 is effective in reducing endocrine responses to pharmacological and behavioral challenge mediated by CRF(1) receptors. NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress. NBI-34041 demonstrates that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders. (last updated: 3/8/2016).
Related Record Type Details
ACTIVE MOIETY
Developer: GlaxoSmithKline; Class: Acenaphthene, Antidepressant, Antispasmodic, Anxiolytic, Irritable bowel syndrome therapy; Mechanism of Action: Corticotropin-releasing factor antagonists; Highest Development Phase: Discontinued for Anxiety disorders, Irritable bowel syndrome and Major depressive disorder
ACTIVE MOIETY
These specific properties and its well-documented safety profile enabled a clinical Phase I study with 24 healthy male subjects receiving NBI-34041 (10, 50, or 100 mg) or placebo for 14 days. Regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis was evaluated by intravenous stimulation with 100 mg of human CRF. Treatment with NBI-34041 did not impair diurnal adrenocorticotropic hormone(ACTH) and cortisol secretion or CRF evoked ACTH and cortisol responses but attenuated the neuroendocrine response to psychosocial stress.